These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8991348)

  • 41. Topical treatment of cutaneous leishmaniasis.
    El-On J; Livshin R; Even-Paz Z; Hamburger D; Weinrauch L
    J Invest Dermatol; 1986 Aug; 87(2):284-8. PubMed ID: 3734476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis.
    Soto J; Grogl M; Berman J; Olliaro P
    Trans R Soc Trop Med Hyg; 1994; 88(6):695-8. PubMed ID: 7886777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Leishmania major: bacterial contamination of cutaneous lesions in experimental animals.
    el-On J; Sneier R; Elias E
    Isr J Med Sci; 1992 Dec; 28(12):847-51. PubMed ID: 1286954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Leishmaniasis with multiple cutaneous nodules].
    Stosiek N; Bogdan C; Solbach W; Hornstein OP
    Dtsch Med Wochenschr; 1992 Nov; 117(46):1752-6. PubMed ID: 1425295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador.
    Krause G; Kroeger A
    Trans R Soc Trop Med Hyg; 1994; 88(1):92-4. PubMed ID: 8154018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis.
    Carneiro G; Santos DC; Oliveira MC; Fernandes AP; Ferreira LS; Ramaldes GA; Nunan EA; Ferreira LA
    J Liposome Res; 2010 Mar; 20(1):16-23. PubMed ID: 19530897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of topical paromomycin on cell-mediated immunity during cutaneous leishmaniasis.
    Frankenburg S; Gross A; Jonas F; Klaus S
    Int J Dermatol; 1993 Jan; 32(1):68-70. PubMed ID: 8425810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of paromomycin sulphate permeation using ex vivo human skin model.
    Khalil EA; Alkawareek MY; Othman G; Tbakhi B; Al-Bakri AG
    Pharm Dev Technol; 2019 Mar; 24(3):390-393. PubMed ID: 29873575
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.
    Burden-Teh E; Wootton CI; Williams HC
    Br J Dermatol; 2015 Apr; 172(4):861-6. PubMed ID: 25354137
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of paromomicin and gentamicin patches in the treatment of cutaneous leishmaniasis.
    Asilian A; Faghihi G; Siadat AH; Hejazi H; Shahtalebi M; Sadeghian G; Mostaghim M; Radan MR
    East Mediterr Health J; 2006 Nov; 12(6):931-3. PubMed ID: 17333845
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.
    Thakur CP; Kanyok TP; Pandey AK; Sinha GP; Messick C; Olliaro P
    Trans R Soc Trop Med Hyg; 2000; 94(4):432-3. PubMed ID: 11127251
    [No Abstract]   [Full Text] [Related]  

  • 53. Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin B.
    Zvulunov A; Cagnano E; Frankenburg S; Barenholz Y; Vardy D
    Pediatr Infect Dis J; 2003 Jun; 22(6):567-9. PubMed ID: 12828157
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Topical paromomycin and gentamicin for new world cutaneous leishmaniasis in Panama.
    Monge-Maillo B; López-Vélez R
    Am J Trop Med Hyg; 2014 Jun; 90(6):1191. PubMed ID: 24898981
    [No Abstract]   [Full Text] [Related]  

  • 55. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom.
    Scott JA; Davidson RN; Moody AH; Grant HR; Felmingham D; Scott GM; Olliaro P; Bryceson AD
    Trans R Soc Trop Med Hyg; 1992; 86(6):617-9. PubMed ID: 1287915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ablative fractional laser resurfacing with topical paromomycin as adjunctive treatment for a recalcitrant cutaneous leishmaniasis wound.
    Basnett A; Nguyen TA; Cannavino C; Krakowski AC
    Lasers Surg Med; 2015 Dec; 47(10):788-91. PubMed ID: 26419328
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leishmania major: histopathological responses before and after topical treatment in experimental animals.
    El-On J; Lang E; Kuperman O; Avinoach I
    Exp Parasitol; 1989 Feb; 68(2):144-54. PubMed ID: 2924878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paromomycin-loaded albumin microspheres: efficacy and stability studies.
    Khan W; Kumar R; Singh S; Arora SK; Kumar N
    Drug Test Anal; 2013 Jun; 5(6):468-73. PubMed ID: 22514145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
    Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
    Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Leishmaniasis chemotherapy--challenges and opportunities.
    Croft SL; Olliaro P
    Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.